CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
Provided By GlobeNewswire
Last update: Jan 3, 2025
Fourth quarter product revenue growth estimated at 22% to 25% year-over-year
Fourth quarter gross margin estimated to improve to approximately 70%
Read more at globenewswire.comNASDAQ:CTSO (2/21/2025, 8:11:17 PM)
1.15
0 (0%)
Find more stocks in the Stock Screener
